

**Florida Breast Cancer Coalition Research Foundation, Inc.  
D/B/A Florida Breast Cancer Foundation, Inc.**

Financial Statements

For the Year Ended June 30, 2025



**FORGE**

FINANCIAL & MANAGEMENT CONSULTING

**Florida Breast Cancer Coalition Research Foundation, Inc.  
D/B/A Florida Breast Cancer Foundation, Inc.**

| <b>Contents</b>  | <b>Page(s)</b> |
|--|----------------|
| <b>Independent Auditors' Report</b>  | 1-3            |
| <b>Financial Statements:</b>   |                |
| Statement of Financial Position  | 4              |
| Statement of Activities  | 5              |
| Statement of Functional Expenses   | 6              |
| Statement of Cash Flows  | 7              |
| Notes to Financial Statements  | 8-15           |
| <b>Independent Auditor's Report on Internal Control over<br/>Financial Reporting and on Compliance and Other Matters<br/>Based on An Audit of Financial Statements Performed in<br/>Accordance with <i>Government Auditing Standards</i></b> | 16-17          |
| <b>Schedule of Findings and Questioned Costs</b>   | 18             |



# FORGE

FINANCIAL & MANAGEMENT CONSULTING

## Independent Auditors' Report

To the Board of Directors of  
Florida Breast Cancer Coalition Research Foundation, Inc.  
d/b/a Florida Breast Cancer Foundation, Inc  
North Miami, Florida

### **Opinion**

We have audited the accompanying financial statements Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc (a nonprofit organization) which comprise the statement of financial position as of June 30, 2025, and the related statement of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc. as of June 30, 2025, and the changes in net assets and its cash flows for the year then ended and in accordance with accounting principles generally accepted in the United States of America.

### **Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Correction of Error**

As discussed in Note 12 to the financial statements, certain errors resulting in overstatement of amounts previously reported for grant expenses as of June 30, 2024, were discovered during the audit. Accordingly, amounts reported for grant expenses have been restated in the June 30, 2025 financial statements now presented, and an adjustment has been made to net assets as of June 30, 2024, to correct the error. Our opinion is not modified with respect to that matter.

## **Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### **Other Reporting Required by Government Auditing Standards**

In accordance with *Government Auditing Standards*, we have also issued our report dated December 10, 2025, on our consideration of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc's internal control over financial reporting and compliance.

*Forge Financial and Management Consulting, Inc.*

West Des Moines, Iowa  
December 10, 2025

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc.**  
**Statement of Financial Position**  
**June 30, 2025**

**Assets:**

Current assets:

|   |    |                  |
|---|----|------------------|
| Cash  | \$ | 5,495,140        |
| Investments   |    | 103,118          |
| Accounts receivable, net of allowance<br>for credit losses of \$-0- |    | 198,365          |
| Prepaid expenses and other assets                                   |    | 16,780           |
| Total current assets  |    | <u>5,813,403</u> |

Long-term assets:

|   |    |                         |
|---|----|-------------------------|
| Fixed assets                            |    | 28,380                  |
| Accumulated depreciation                |    | <u>(14,547)</u>         |
| Net fixed assets                        |    | 13,833                  |
| Operating lease right-of-use asset, net |    | <u>18,923</u>           |
| Total long-term assets                  |    | <u>32,756</u>           |
| Total assets                            | \$ | <u><u>5,846,159</u></u> |

**Liabilities:**

Current liabilities:

|   |    |               |
|---|----|---------------|
| Accounts payable                            | \$ | 22,282        |
| Accrued payroll                             |    | 29,023        |
| Credit card payable                         |    | 10,914        |
| Operating lease liability - current portion |    | <u>18,923</u> |
| Total current liabilities                   |    | <u>81,142</u> |
| Total liabilities                           |    | <u>81,142</u> |

**Net assets:**

Without donor restrictions:

|                                  |    |                         |
|----------------------------------|----|-------------------------|
| Undesignated                     |    | 4,578,357               |
| Designated by Board              |    | 116,054                 |
| With donor restrictions          |    | <u>1,070,606</u>        |
| Total net assets                 |    | <u>5,765,017</u>        |
| Total liabilities and net assets | \$ | <u><u>5,846,159</u></u> |

See accompanying notes to consolidated financial statements.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc.**  
**Statement of Activities**  
**For the Year Ended June 30, 2025**

|  | <u>Without Donor<br/>Restrictions</u> | <u>With Donor<br/>Restrictions</u> | <u>Totals</u>    |
|--|---------------------------------------|------------------------------------|------------------|
| <b>Revenue and other support:</b>  |                                       |                                    |                  |
| Thrift shop revenues   | \$ 2,467,050                          | -                                  | 2,467,050        |
| License plate revenues   | 87,321                                | 425,454                            | 512,775          |
| Contributions  | 693,296                               | -                                  | 693,296          |
| In-kind contribution   | 24,443                                | -                                  | 24,443           |
| Investment income  | 25,082                                | -                                  | 25,082           |
| ERTC revenue   | 134,746                               | -                                  | 134,746          |
| Other revenue  | 100                                   | -                                  | 100              |
|  | <u>3,432,038</u>                      | <u>425,454</u>                     | <u>3,857,492</u> |
| Net assets released from restrictions  | <u>453,164</u>                        | <u>(453,164)</u>                   | <u>-</u>         |
| Total revenue and other support and<br>net assets released from restrictions | <u>3,885,202</u>                      | <u>(27,710)</u>                    | <u>3,857,492</u> |
| <b>Expenses:</b>   |                                       |                                    |                  |
| Program services   | <u>2,119,516</u>                      | <u>-</u>                           | <u>2,119,516</u> |
| Supporting activities:   |                                       |                                    |                  |
| General and administrative   | 157,098                               | -                                  | 157,098          |
| Fundraising  | 146,155                               | -                                  | 146,155          |
| Total supporting activities  | <u>303,253</u>                        | <u>-</u>                           | <u>303,253</u>   |
| Total expenses   | <u>2,422,769</u>                      | <u>-</u>                           | <u>2,422,769</u> |
| Change in net assets   | 1,462,433                             | (27,710)                           | 1,434,723        |
| <b>Net assets, beginning of year, as restated</b>                            | <u>3,231,978</u>                      | <u>1,098,316</u>                   | <u>4,330,294</u> |
| <b>Net assets, end of year</b>   | <u>\$ 4,694,411</u>                   | <u>1,070,606</u>                   | <u>5,765,017</u> |

See accompanying notes to consolidated financial statements.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc.**  
**Statement of Functional Expenses**  
**For the Year Ended June 30, 2025**

|                            | Program<br>Services | Supporting Services           |                | Totals           |
|----------------------------|---------------------|-------------------------------|----------------|------------------|
|                            |                     | General and<br>Administrative | Fund-Raising   |                  |
| Advocacy/education/grants  | \$ 272,792          | -                             | -              | 272,792          |
| Salaries and benefits      | 580,453             | 131,570                       | 61,915         | 773,938          |
| Grants and awards          | 921,438             | -                             | -              | 921,438          |
| Marketing/awareness        | 112,465             | 7,497                         | 29,991         | 149,953          |
| Community relations        | 29,199              | -                             | 29,199         | 58,398           |
| Computer expenses          | 15,922              | 419                           | 419            | 16,760           |
| Professional fees          | 38,070              | 5,077                         | 7,615          | 50,762           |
| Administrative and other   | 59,943              | 7,992                         | 11,989         | 79,924           |
| Rent                       | 60,369              | 1,245                         | 622            | 62,236           |
| Depreciation expense       | 334                 | 48                            | 95             | 477              |
| Supplies                   | 2,442               | 326                           | 488            | 3,256            |
| Postage and delivery       | 6,169               | 657                           | 1,398          | 8,224            |
| Repairs and maintenance    | 4,584               | 407                           | 102            | 5,093            |
| Telecommunications         | 4,844               | 646                           | 969            | 6,459            |
| Utilities                  | 2,419               | 323                           | 484            | 3,226            |
| Insurance                  | 3,877               | 518                           | 776            | 5,171            |
| Bank charges/merchant fees | 4,196               | 373                           | 93             | 4,662            |
| Total expenses             | \$ <u>2,119,516</u> | <u>157,098</u>                | <u>146,155</u> | <u>2,422,769</u> |

See accompanying notes to consolidated financial statements.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc.**  
**Statement of Cash Flows**  
**For the Year Ended June 30, 2025**

---

|   |                            |
|---|----------------------------|
| <b>Cash flows from operating activities:</b>  |                            |
| Change in net assets  | \$ 1,434,723               |
| Adjustments to reconcile change in net assets<br>to net cash provided by operating activities |                            |
| Depreciation  | 477                        |
| Reduction of right-of-use assets  | 30,783                     |
| Change in operating lease liabilities   | (1,194)                    |
| (Increase) decrease in:   |                            |
| Accounts receivable   | (14,883)                   |
| Prepaid expenses and other assets   | (13,918)                   |
| Increase (decrease) in:   |                            |
| Accounts payable and accrued expenses   | 21,158                     |
| Operating lease liabilities   | (29,589)                   |
| Net cash provided (used) by operating activities  | <u>1,427,557</u>           |
| <b>Cash flows from investing activities:</b>  |                            |
| Reinvested investment income  | (9,282)                    |
| Purchases of fixed assets   | (14,310)                   |
| Net cash provided (used) by investing activities  | <u>(23,592)</u>            |
| <b>Net increase (decrease) in cash and cash equivalents</b>                                   | <b>1,403,965</b>           |
| <b>Cash and cash equivalents, beginning of year</b>   | <b><u>4,091,175</u></b>    |
| <b>Cash and cash equivalents, end of year</b>   | <b>\$ <u>5,495,140</u></b> |

See accompanying notes to consolidated financial statements.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

---

**Note 1 - Significant Accounting Policies**

*Nature of Activities* - The Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc. (the "Foundation") has as its mission to save the lives of those impacted by breast cancer by supporting scientific research, community education, public policy through advocacy and community-based organizations. It achieves its mission by raising public awareness regarding breast cancer through providing community education and providing resource materials and information to the Florida community. The Foundation also awards grants to qualifying foundations in the State of Florida. All funding raised is used solely in the State of Florida.

*Basis of Accounting* - The Foundation prepares its financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

*Basis of Presentation* - The financial statements of the Foundation have been prepared to report regarding its financial position and activities according to the following net asset classifications:

*Net assets without donor restrictions* - Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation's management and the board of directors.

*Net assets with donor restrictions* - Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

*Use of Estimates* - The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

*Cash and Cash Equivalents* - For purposes of reporting the statement of cash flows, the Foundation considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid investments with a maturity of three months or less, when purchased, to be cash equivalents.

*Investments* - The Foundation's investments are stated at fair value. Fair value is the price that would be received to sell an asset or paid to transfer liability in an orderly transaction between willing market participants at the measurement date. Purchases and sales of securities are recorded on a trade-date basis. Investment income or loss (including realized and unrealized gains and losses on investments, interest and dividends) is included in the statement of activities as an increase or decrease in net assets without donor restriction unless income or loss is restricted by donor or law. Restricted gains and investment income, where the restrictions are met in the same reporting period as the income earned, are recorded as unrestricted support. The Foundations also has a certificate of deposit, which have a remaining maturity of one year or less. The certificate of deposit is recorded at amortized cost, which approximates fair value.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

---

**Note 1 - Significant Accounting Policies (Continued)**

*Accounts Receivable* - Accounts receivable consist principally of amounts due from the thrift store and grantor agencies pursuant to the terms of the respective agreements. Accounts receivable are stated at net realizable value. Allowances are provided for amounts estimated to be uncollectible based on historical experience and any specific collection issues that the Foundation has identified. It is the Foundation's policy to charge uncollectible receivables against the allowance when management determines that the related balance will not be collected. Management determined that an allowance for doubtful accounts was not necessary at June 30, 2025. As of June 30, 2025 and 2024, the Foundation has accounts receivable of \$198,365 and \$183,482, respectively.

*Property and Equipment* - Property and equipment are stated at cost, if purchased, or fair market value at the date of the gift, if donated. All acquisitions of property and equipment in excess of \$1,000 are capitalized. Property and equipment consist of computers, furniture, equipment, and improvements. Property and equipment are depreciated on a straight-line basis over a range of 3-15 years. Maintenance, repairs, and minor improvements are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

*Revenue From Contracts with Customers* - Thrift shop revenue is recognized when the product is sold to the customer. The Foundation has a contract with a thrift store operator who reimburses the Foundation with a fee based on the amount of products sold.

*License plate revenues* - The Foundation is the only organization in the State of Florida that receives funds from the sale of the "End Breast Cancer" specialty license plates from which 80% of the funds are received with donor restriction for grant purposes and 20% are received without donor restriction and are available to be used for operational/ administrative expenses.

*VCP Program revenues* - The Foundation also receives funds from the voluntary checkoff program (VCP). The VCP program allows motor vehicle applicants to make voluntary contributions to "End Breast Cancer" during license plate registration or renewal. All of the funds received from the VCP are restricted for grant purposes and are included under License Plate Revenues on the Statement of Activities. All grant awards by the Foundation are provided only to organizations within the State of Florida.

*Contributions* - Contributions are recognized when the donor makes a promise to give to the Foundation that is, in substance, unconditional. Unconditional contributions are recognized when made. Conditional contributions are recognized when the donor-imposed barrier stipulated in the agreement has been overcome. Contributions are classified within the statement of activities as without donor restrictions or with donor restrictions depending upon the existence and/or nature of the donor restrictions. Contributions are recorded as net assets with donor restrictions if they are received with donor stipulations or time considerations as to their use. Net assets with donor restrictions are reclassified to net assets without donor restrictions when either the purpose restriction is satisfied, or the time restriction expires. Contributions with donor restrictions that are both received and released in the same period are classified as without donor restrictions in the statement of activities.

*Research Awards and Grants* - The Foundation awards funds to support grassroots educational programs as well as breast cancer research programs at major institutions throughout Florida.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

---

**Note 1 - Significant Accounting Policies (Continued)**

*Income Taxes* - The Foundation is a non-profit corporation as defined by Section 501(c)(3) of the U.S. Internal Revenue Code and as such is subject to state and federal income taxes only on unrelated business taxable income. The Foundation believes that it has appropriate support for all tax positions taken and, as such, does not have any uncertain tax positions that are material to the financial statements. The Foundation is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

*Functional Allocation of Expenses* - The costs of providing the various programs and other activities have been detailed in the accompanying statement of functional expenses and are summarized on a functional basis in the accompanying statement of activities. Salaries and other expenses, which are associated with a specific program, are charged directly to that program. Salaries for staff which support more than one program, are allocated to the various programs based on an analysis of time spent and effort. Other expenses which benefit more than one program are allocated based on estimates made by management.

*Contributed Materials and Services* - Contributed materials and services are reflected in the accompanying financial statements at their estimated fair value, if reasonably determined. The contributions of services are recognized if the services received (a) create or enhance non-financial assets, or (b) require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not provided by donations. In-kind contributions consist primarily of donating store and office space.

The Foundation utilizes the services of volunteers in their advocacy work and programs. Because there is no objective means of valuing such services, amounts for such donated services are not reflected in the financial statements as they do not meet the criteria for recording.

*Leases* - The Foundation has one noncancellable operating lease for office space. The Foundation determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing arrangement are changed. Variable payments are included in the future lease payments when those variable payments depend on an index or a rate.

Right-of use (ROU) assets represent the Foundation's right to use an underlying asset for the lease term, and lease liabilities represent the Foundation's obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Foundation uses the implicit rate when it is readily determinable. Since most of the Foundation's leases do not provide an implicit rate, to determine the present value of lease payments, management uses the Foundation's incremental borrowing rate based on the information available at lease commencement. Operating lease ROU assets also includes any lease payments made and excludes any lease incentives. The Foundation recognizes operating lease expense for actual rent paid, generally plus or minus a straight-line adjustment for estimated rate increases, if applicable. The Foundation's lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

---

**Note 1 - Significant Accounting Policies (Continued)**

*Leases (continued)* - The Foundation has elected, for all asset classes, to not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less at lease commencement, and do not include an option to purchase the underlying asset that the Foundation is reasonably certain to recognize. The Foundation recognizes lease costs associated with short-term leases on a straight-line basis over the lease term.

The Foundation has elected for all assets classes to account for each separate lease component of a contract and its associated non-lease components as a single lease component.

*New Accounting Pronouncement* - On July 30, 2025 the FASB issued *ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets*. The standard allows the Foundation to elect a practical expedient to base the allowance for credit losses on current economic conditions at the balance sheet date. Additionally, the standard permits the Foundation to make an accounting policy election to consider collections received after the balance sheet date but before the financial statements are available to be issued.

The Foundation early adopted ASU 2025-05 prospectively. As a result, the Foundation applied the practical expedient and elected the policy to include subsequent collections through October 17 2025, which reduced complexity and improved the accuracy of the allowance estimate.

*Date of Management’s Review* - Management has evaluated subsequent events through December 10, 2025, the date when the financial statements were available to be issued.

**Note 2 - Liquidity and Availability**

The following represents the Foundation’s financial assets at June 30, 2025:

|  |                     |
|--|---------------------|
| Financial assets at year-end:  |                     |
| Cash and cash equivalents  | \$ 5,495,140        |
| Investments  | 103,118             |
| Accounts receivable  | 198,365             |
| Total financial assets   | <u>5,796,623</u>    |
| Less financial assets not available to be used for general expenditures within one year: |                     |
| Net assets with donor restrictions   | <u>1,070,606</u>    |
|  | <u>1,070,606</u>    |
| Financial assets available to meet general expenditures over the next twelve months      | <u>\$ 4,726,017</u> |

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

**Note 3 - Fair Value Measurement**

The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

Basis of Fair Value Measurement

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
- Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly;
- Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. These inputs reflect the Foundation’s assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. Because Level 3 valuations rely on significant unobservable inputs, the determination of fair value is inherently uncertain, and the values reported could differ if different assumptions were used or if market conditions change.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following tables summarize financial instruments at fair value on a recurring basis by classification within the fair value hierarchy as of June 30, 2025:

| <b>Description</b>                           | <b>June 30,<br/>2025</b> | <b>Quoted Prices<br/>In Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</b> | <b>Other<br/>Observable<br/>Inputs<br/>(Level 2)</b> | <b>Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</b> |
|--|--------------------------|---|--|--|
| Investments                                  |                          |   |  |  |
| Investment held at<br>Miami Foundation, Inc. | \$ 80,648                | -   | 80,648   | -  |

*Investments held at Miami Foundation, Inc.*- The values of the assets invested at Miami Foundation, Inc. are determined by calculating the Foundation’s net asset value (“NAV”) in the pool. The Foundation has the ability to observe the inputs to the valuation and redeem the investment at NAV upon request and are reported as Level 2 investments as the investment pool has a readily determinable fair value. The investment held at Miami Foundation, Inc. is invested in a balanced pool and principally includes fixed income and equity investment funds. The investments held at Miami Foundation, Inc. have no unfunded commitments as of June 30, 2025. Additionally, other than a 1-day notice and bi-monthly redemption frequency, there are no explicit restrictions on the redemption of such investments.

There have been no changes in the techniques and inputs used as of June 30, 2025.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

---

**Note 4 - Concentrations of Credit Risk**

From time to time, the Foundation maintains its cash in deposit accounts at financial institutions that exceed the Federal Deposit Insurance Corporation (“FDIC”) limits. The FDIC insures depositors up to \$250,000. The Foundation maintains these balances in high quality financial institutions, which it believes limits its risk.

**Note 5 - Concentrations**

For the year ended June 30, 2025, the Foundation received approximately 13% of its revenue from the State of Florida, Department of Highway Safety and Motor Vehicles (the “Department”). The Foundation also received approximately 64% of its revenue from the Thrift Store. As the revenue from the Department and the Thrift Store is significant to the overall operations of the Foundation, any significant reduction or loss of funding from the Department or Thrift Store may affect the Foundation’s ability to operate in its present form.

**Note 6 - Thrift Store**

The Foundation has an agreement with a thrift store operator in which items (clothing, furniture, etc.) are donated to the Foundation and are sold by the thrift store operator. The Foundation earns a fee based on a percentage of gross thrift shop store sales to help fund efforts toward breast cancer advocacy, education and research. The agreement with the thrift store operator runs through June 2028. Revenues related to the thrift store were \$2,467,050 for the fiscal year ended June 30, 2025.

**Note 7 - Grant Commitments**

The Foundation provides resources to various institutions to conduct research related to breast cancer. These projects include clinical research and educational initiatives intended to improve health outcomes and advance efforts to find a cure for breast cancer. For the year ended June 30, 2025, the Foundation disbursed approximately \$921,000 in grants and awards. These grants are conditional upon the execution of grant agreements and satisfaction of specified programmatic requirements. All grants are made to Florida-based foundations and are paid from donor-restricted funds. The Foundation also disbursed approximately \$164,000 in advocacy, education, and grant-related funding during the year ended June 30, 2025. The Foundation participates in state and local programs that are subject to audit by the respective agencies. Any disallowed funds received or to be received under these programs may constitute a liability in the amount of the disallowed funds. Management does not believe that any potential disallowed funds would have a significant effect on the financial statements.

**Note 8 - In-Kind Contribution**

The Foundation currently receives rent-free use of store and office space from Oviedo Mall in Oviedo, Florida in exchange for exclusive sponsorship in accordance with the lease agreement. The current lease agreement expires on January 31, 2026, and is presently on a month-to-month basis. Accordingly, the fair value of the annual rent is determined each year by the Foundation’s management, and the fair value of the rent is recorded as an in-kind contribution and rent expense in the accompanying statement of activities.

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

**Note 9 - Leases**

The Foundation has one noncancelable operating lease for office space expiring through March 2026. Under the terms, the monthly payment is \$2,441. The Foundation classifies the lease as an operating lease. Payments due under the lease contract include fixed payments.

| Lease Cost           | Classification | Year Ended<br>June 30, 2025 |
|----------------------|----------------|-----------------------------|
| Operating lease cost | Rent           | \$ 29,296                   |
| In-kind lease cost   | Rent           | 23,704                      |
| Variable lease costs | Rent           | 9,236                       |
| Total lease cost     |                | \$ 62,236                   |

The following is a schedule by year of minimum lease payments required under the leases as of June 30, 2025:

| Year Ending June 30,               | Operating<br>Leases |
|------------------------------------|---------------------|
| 2026                               | \$ 19,531           |
| Total lease payments               | 19,531              |
| Less: Interest                     | 608                 |
| Present value of lease liabilities | \$ 18,923           |

The following table presents the weighted average remaining lease term and discount rate as of June 30, 2025:

|  |            |
|--|------------|
| Weighted average remaining lease term (years): |            |
| Operating leases                               | 0.67 years |
| Weighted average discount rate:                |            |
| Operating leases                               | 8.50%      |

**Note 10 - Board Designated Net Assets and Net Assets Without Donor Restrictions**

Net assets without donor restrictions at June 30, 2025 are as follows:

|   |              |
|---|--------------|
| Undesignated                                  | \$ 4,578,357 |
| Amounts Designated by the Board of Directors: |              |
| Scholarship Fund                              | 11,831       |
| Broward County Programs                       | 104,223      |
| Total Net Assets Without Donor Restrictions   | \$ 4,694,411 |

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Notes to Financial Statements**  
**June 30, 2025**

---

**Note 11 - Net Assets With Donor Restrictions**

Net assets with donor restrictions consist of license plate revenues and donations from the voluntary checkoff program (“VCP”). For the year ended June 30, 2025, contributions with donor restrictions include license plate revenues and donations from VCP totaling \$425,454. These amounts are restricted for grant awards to be provided for breast cancer research and education. Research and education funding can be made available for:

- Basic, clinical, and translational breast cancer research, with priority given to Young Investigator Epidemiological studies of breast cancer
- Research on possible links between breast cancer and the environment
- Psychoimmunological research
- Innovative awards and idea grants

Net assets with donor restrictions consisted of the following as of June 30:

|   |                     |
|---|---------------------|
| Subject to expenditure for specified purpose: |                     |
| Breast Cancer Research and Education          | \$ <u>1,070,606</u> |
| Total net assets with donor restrictions      | \$ <u>1,070,606</u> |

Net assets with restrictions for specified purposes that were released from restrictions by incurring expenses satisfying the specific use restrictions imposed by the donors consisted of the following as of December 31:

|                                    |                   |
|------------------------------------|-------------------|
| Purpose restrictions accomplished: |                   |
| Grant Awards: Scientific           | \$ <u>453,164</u> |
| Total                              | \$ <u>453,164</u> |

**Note 12 - Prior Period Restatement**

During the fiscal year ended June 30, 2025, the Foundation determined that certain grant expenses totaling \$399,755 had been incorrectly recorded in the fiscal year ended June 30, 2024. These grant expenditures were not executed or incurred until the current fiscal year. Under U.S. GAAP, grant expenses should be incurred when the grant is made or executed.

Accordingly, the Foundation has restated the beginning net assets as of July 1, 2024 to remove the previously recorded expenses, and has recorded the \$399,755 of grant expenses in the fiscal year ended June 30, 2025, the period in which the grants were fully executed.

**Note 13 - Subsequent Events**

During the year ended June 30, 2025, the Foundation approved grant awards totaling approximately \$907,500. Although these grants were formally approved by the Board, the underlying grant agreements were not fully executed and disbursed until after June 30, 2025.



# FORGE

FINANCIAL & MANAGEMENT CONSULTING

Independent Auditors' Report on Internal Control  
Over Financial Reporting and on Compliance and Other Matters  
Based on an Audit of Financial Statements  
Performed in Accordance with Government Auditing Standards

To the Board of Directors of  
Florida Breast Cancer Coalition Research Foundation, Inc.  
d/b/a Florida Breast Cancer Foundation, Inc  
North Miami, Florida

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of June 30, 2025, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements and have issued our report thereon dated December 10, 2025.

## **Report on Internal Control over Financial Reporting**

In planning and performing our audit of the financial statements, we considered Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc.'s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc.'s internal control. Accordingly, we do not express an opinion on the effectiveness of Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc.'s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. We consider the deficiency described in the Foundation's schedule of findings as item 2025-001 to be a material weakness.

A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of the internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. We identified a certain deficiency in internal control, described in the accompanying schedule of findings and questioned costs as item 2025-001 that we consider to be material weaknesses.

### **Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether Florida Breast Cancer Coalition Research Foundation, Inc. d/b/a Florida Breast Cancer Foundation, Inc.'s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Foundation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Foundation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Forge Financial and Management Consulting, Inc.*

West Des Moines, Iowa  
December 10, 2025

**Florida Breast Cancer Coalition Research Foundation, Inc.**  
**D/B/A Florida Breast Cancer Foundation, Inc**  
**Schedule of Findings and Responses**  
**June 30, 2025**

---

Part I: Summary of independent auditors' results:

1. An unmodified opinion was issued on the financial statements.
2. There were no significant deficiencies and one material weakness in internal control over financial reporting noted as part of our audit. Additional material weaknesses or significant deficiencies may exist that have not been uncovered.
3. The audit did not disclose any non-compliance that is material to the financial statements.

Part II: Finding(s) related to the financial statements:

**Auditing Finding 2025-001 - Material Audit Adjustments**

**Criteria:** The financial statements should be recorded on the accrual basis in accordance with U.S. generally accepted accounting principles.

**Condition:** During our audit, we identified misstatements that were corrected during the audit. The misstatements identified affected grant expenses, and the misstatements were material individually and in the aggregate.

**Cause:** The misstatements occurred because certain grant expenses were recorded prematurely. Although the Foundation approved certain grants during the year, the related grant agreements were not executed until after year-end. The Foundation prepared and held checks at year-end pending the execution of these agreements. However, these held checks should not have been removed from cash or recognized as expenses until the grant agreements were fully executed and the checks were released. This resulted in expenses being recorded in the incorrect reporting period.

**Effect:** The financial statements were materially misstated, and journal entries were necessary to correct.


**Recommendation:** We recommend that Management strengthen internal controls over revenue and grant-related transactions, including not recording grant expenses until they have been executed.

**Views of responsible officials:** Management agrees with the finding and will work to improve procedures around its financial reporting.

**Summary Schedule of Prior Audit Findings**

---

| <b>Findings</b>          | <b>Status</b> |
|--------------------------|---------------|
| None in prior year audit | N/A           |



**FORGE**

FINANCIAL & MANAGEMENT CONSULTING